X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
ENV-101 (taladegib) is an oral small molecule inhibitor of the Hedgehog (Hh) signaling pathway. It is being evaluated in phase 2 clinical studies for the treatment of idiopathic pulmonary fibrosis.
Lead Product(s): Taladegib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ENV-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2024
Details:
Endeavor will use the financing proceeds to advance the clinical development of ENV-101, its lead candidate for the treatment of idiopathic pulmonary fibrosis.
Lead Product(s): Taladegib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ENV-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AyurMaya
Deal Size: $132.5 million Upfront Cash: Undisclosed
Deal Type: Series C Financing April 24, 2024
Details:
ENV-101 (taladegib) is an oral small molecule inhibitor of the Hedgehog (Hh) signaling pathway. It is being evaluated in phase 2 clinical studies for the treatment of idiopathic pulmonary fibrosis.
Lead Product(s): Taladegib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ENV-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2024
Details:
ENV-101 (taladegib) is a small-molecule inhibitor of the Hedgehog (Hh) signaling pathway, which plays a critical role in idiopathic pulmonary fibrosis disease pathology.
Lead Product(s): Taladegib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ENV-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2023
Details:
The partnership helps identify patients whose cancers harbor the PTCH1 mutation and may be eligible for Endeavor’s clinical trial for ENV-101 (taladegib). The xCures platform also enables patients to find more suitable treatment options if they are ineligible.
Lead Product(s): Taladegib
Therapeutic Area: Oncology Product Name: ENV-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: xCures
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 31, 2022
Details:
ENV-101 (taladegib), an orally available small molecule inhibitor of the Hedgehog signaling pathway, has already demonstrated preliminary clinical efficacy and safety in nearly 200 subjects enrolled across six completed studies.
Lead Product(s): Taladegib
Therapeutic Area: Oncology Product Name: ENV-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2022
Details:
Proceeds will support the Endeavor’s pipeline, including ENV-101 (taladegib), a small molecule inhibitor of PTCH1 receptor, for the treatment of cancer and idiopathic pulmonary fibrosis and ENV-201, a small molecule inhibitor of ULK1/2 for the treatment of KRAS-driven cancers.
Lead Product(s): Taladegib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ENV-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ally Bridge Group
Deal Size: $101.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing February 07, 2022
Details:
Proceeds from the financing will be used to advance taladegib, an inhibitor of the Hedgehog pathway, into two Phase 2 clinical studies for the treatment of idiopathic pulmonary fibrosis (IPF) in 2021.
Lead Product(s): Taladegib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ENV-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Omega Funds
Deal Size: $62.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 07, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
